Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.52 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | TPH1 | P17752 | 20/20 | 0.93 |
| ▸ | TPH2 | Q8IWU9 | 11/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.52 |
| ▸ | CCKAR | P32238 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2927928 | 1.00 | TPH1 (0.93) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| Fumaric Acid SCHEMBL2927924 | 1.00 | TPH1 (0.93) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL2364480 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL29391423 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL870345 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL870344 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL308718 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL308719 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL13878219 | 0.96 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL12128916 | 0.91 | TPH1 (0.89) | TPH1TPH2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231618-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090099206-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| WO-2009048864-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | WO | claimed |
| US-9150521-B2 | Methods of preventing and treating diabetes by inhibiting serotonin synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140378489-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2014-12-25 | — | — | US | disclosed |
| US-8614222-B2 | Methods of preventing and treating low bone mass diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130338176-A1 | METHODS OF PREVENTING AND TREATING HYPERLIPIDEMIA OR ATHEROSCLEROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2013116538-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2012058598-A1 | METHODS OF PREVENTING AND TREATING HYPERLIPIDEMIA OR ATHEROSCLEROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012054388-A1 | TPH1 INHIBITORS AND BISPHOSPHONATES FOR PREVENTING AND TREATING LOW BONE MASS DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2231618-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010056992-A1 | METHODS OF PREVENTING AND TREATING LOW BONE MASS DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090099206-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2009048864-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338176-A1 | METHODS OF PREVENTING AND TREATING HYPERLIPIDEMIA OR ATHEROSCLEROSIS | TPH1, PON1, APOB | SLC6A2 150/4885SLC6A4 77/4885SLC6A3 462/4885 |
| US-20140378489-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | TPH1, TPH2, HTR1A | SLC6A2 33/4885SLC6A4 14/4885SLC6A3 49/4885 |
| US-20090099206-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3'-METHOXYBIPHENYL-4-YL)ETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID AND METHODS OF THEIR USE | PCCA, ANXA6, CPS1 | SLC6A2 348/4885SLC6A4 280/4885SLC6A3 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.